DE69629436D1 - Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen - Google Patents

Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen

Info

Publication number
DE69629436D1
DE69629436D1 DE69629436T DE69629436T DE69629436D1 DE 69629436 D1 DE69629436 D1 DE 69629436D1 DE 69629436 T DE69629436 T DE 69629436T DE 69629436 T DE69629436 T DE 69629436T DE 69629436 D1 DE69629436 D1 DE 69629436D1
Authority
DE
Germany
Prior art keywords
patient
endothel
lining
effects
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69629436T
Other languages
English (en)
Other versions
DE69629436T2 (de
Inventor
Anthony Ernest Bolton
Ernest Davidson Cooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509197.1A external-priority patent/GB9509197D0/en
Priority claimed from GBGB9522475.4A external-priority patent/GB9522475D0/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DE69629436D1 publication Critical patent/DE69629436D1/de
Publication of DE69629436T2 publication Critical patent/DE69629436T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69629436T 1995-05-05 1996-05-03 Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen Expired - Fee Related DE69629436T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9509197.1A GB9509197D0 (en) 1995-05-05 1995-05-05 Endothelial lining effects
GB9509197 1995-05-05
GB9522475 1995-11-02
GBGB9522475.4A GB9522475D0 (en) 1995-11-02 1995-11-02 Treatment of raynauds phenomenon
PCT/CA1996/000282 WO1996034613A1 (en) 1995-05-05 1996-05-03 Endothelial lining effects and treatment of vasospastic disorders

Publications (2)

Publication Number Publication Date
DE69629436D1 true DE69629436D1 (de) 2003-09-18
DE69629436T2 DE69629436T2 (de) 2004-06-17

Family

ID=26306991

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69629436T Expired - Fee Related DE69629436T2 (de) 1995-05-05 1996-05-03 Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen

Country Status (11)

Country Link
EP (1) EP0768886B1 (de)
JP (1) JPH10506636A (de)
AT (1) ATE246929T1 (de)
AU (1) AU721530B2 (de)
CA (1) CA2194485C (de)
DE (1) DE69629436T2 (de)
DK (1) DK0768886T3 (de)
ES (1) ES2205026T3 (de)
NZ (1) NZ306395A (de)
PT (1) PT768886E (de)
WO (1) WO1996034613A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
EP1011696B1 (de) * 1997-09-12 2003-11-12 Vasogen Ireland Limited Behandlung von stress und vorbehandlng gegen stress
US6432399B1 (en) 1997-09-12 2002-08-13 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
NZ512849A (en) * 1999-01-12 2003-02-28 Ct De Rech Du Ct Hospitalier D Pre-conditioning against cell death
CA2271190A1 (en) 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
PT1214037E (pt) * 1999-09-16 2004-08-31 Vasogen Ireland Ltd Aparelho e processo para o condicionamento de sangue de mamiferos
AU7500200A (en) 1999-09-24 2001-04-30 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
CA2309417A1 (en) 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
AU3506293A (en) * 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
DE69332087T2 (de) * 1992-02-07 2002-10-24 Etobicocke Vasogen Inc. Verfahren zur erhöhung den stickoxidkonzentration im blut
AU1524095A (en) * 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells

Also Published As

Publication number Publication date
DK0768886T3 (da) 2003-12-01
NZ306395A (en) 2000-02-28
AU721530B2 (en) 2000-07-06
EP0768886B1 (de) 2003-08-13
AU5494496A (en) 1996-11-21
WO1996034613A1 (en) 1996-11-07
ES2205026T3 (es) 2004-05-01
PT768886E (pt) 2003-12-31
CA2194485A1 (en) 1996-11-07
DE69629436T2 (de) 2004-06-17
CA2194485C (en) 2001-09-18
JPH10506636A (ja) 1998-06-30
EP0768886A1 (de) 1997-04-23
ATE246929T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE191506T1 (de) Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DE69731540D1 (de) Behandlung von diarrhoe
ES2080837T3 (es) Tratamiento de estados y enfermedades.
DE69629436D1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE232396T1 (de) Oxydiertes thymosin beta 4
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
TR199901385T2 (xx) Piperidin t�revleri.
ATE309807T1 (de) Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee